# OnCo record lyell-immunopharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/lyell-immunopharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "lyell-immunopharma" ;
  schema:name "Lyell Immunopharma"@en ;
  schema:description "Lyell makes next-generation CAR T-cell therapies designed to last longer in the body and resist exhaustion. Its lead product, ronde-cel, targets two proteins on lymphoma cells at once and is in pivotal trials for large B-cell lymphoma."@en ;
  schema:url <https://onco.cc/companies/lyell-immunopharma/>, <https://www.lyell.com> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lyell_Immunopharma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q106411716> ;
  schema:citation <https://www.lyell.com>, <https://www.sec.gov/Archives/edgar/data/1806952/000162828026054330/lyel-20260806x8kexx991.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/rondecabtagene-autoleucel/> ;
  onco:trials <https://onco.cc/trials/nct05826535/>, <https://onco.cc/trials/nct05319314/> .